Bexarotene

贝沙罗汀

Report date: 2026/04/16 20:00:17
NME

Base Information

Drug NameBexarotene
Drug Alias Namebexaroteno蓓萨罗丁bexarotenumTargrexinTargretin +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRetinoid X receptor alpha agonistsRetinoid X receptor gamma agonistsRetinoid X receptor beta agonists
TargetsRetinoid X receptor gammaRetinoid X receptor alphaRetinoid X receptor beta
Therapy Area/IndicationsSchizophreniaCushing SyndromePsoriasis +[16] 
Global Approved IndicationsLymphoma, T-Cell, Cutaneous
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1999/12/29
Country/TerritoryUnited StatesIsraelEU +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesLigand Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesBausch Health Us LlcBushu Pharmaceuticals Ltd. Kawagoe FactoryNational Cancer Institute +[7] 
Inactive CompaniesUniversity Of Medicine And Dentistry Of New JerseyLigand Pharmaceuticals IncRexceptor Inc +[9] 
Active IndicationsBreast NeoplasmsBreast Carcinoma In SituCarcinoma, Lobular +[5] 
Inactive IndicationsSchizophreniaCushing SyndromePsoriasis +[11] 

Other Information

ATC CodeL01XF03
Related LinksWikipediaDrugBankKEGG